查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612742

癌症生物标记市场：按生物标记类型、癌症类型、技术、应用、最终用户 - 2025-2030 年全球预测

Cancer Biomarkers Market by Biomarker Type (Genetic, Protein), Cancer Type (Blood Cancer, Breast Cancer, Colorectal Cancer), Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症生物标记市场价值为283.1亿美元，预计到2024年将达到312.3亿美元，复合年增长率为10.71%，预计到2030年将达到577.5亿美元。

癌症生物标记是存在于血液、其他体液和组织中的生物分子，显示癌症的存在。其范围包括检测、诊断、预后和治疗监测，这在个人化医疗中非常重要。癌症生物标记研究对于早期检测、更准确的诊断和改善患者预后的客製化治疗至关重要。生物标记广泛应用于临床诊断、药物发现研发、癌症研究、放射学、病理学等。最终用途多种多样，包括医院、实验室、诊断中心、生技和製药公司。关键的成长要素包括癌症发病率上升、癌症基因组研究资金增加、体学技术进步以及对非侵入性检测程序的需求不断增加。潜在的机会在于蛋白质体学、基因组学和生物资讯学的进步，这些进步有可能发现新颖的生物标记物，以及医疗基础设施正在迅速改善的新兴市场。然而，他们面临着诸如生物标誌物发现和检验的高成本、监管复杂性以及影响结果解释的生物标誌物表达的可变性等挑战。为了克服这些问题，重要的是利用巨量资料分析和人工智慧来提高预测准确性并整合多组体学资料以发现更准确的标记。最佳创新领域包括开发液态切片技术、利用微型RNA和胞外体探索生物标记以及提高就地检验能力。学术机构、医疗保健提供者和生技公司之间的合作可以加速创新并将新的解决方案推向市场。癌症生物标记市场是一个高度动态和竞争的市场，其特点是技术快速发展和不断创新，以满足癌症早期检测和个人化治疗的迫切需求。采用次世代定序（NGS）技术并探索资料分析中的人工智慧等综合方法可以提供竞争优势。

主要市场统计
基准年[2023] 283.1亿美元
预计年份 [2024] 312.3亿美元
预测年份 [2030] 577.5亿美元
复合年增长率（%） 10.71%

市场动态：揭示快速发展的癌症生物标记市场的关键市场洞察

供需的动态交互作用正在改变癌症生物标记市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 人群中癌症盛行率增加
    • 增加早期癌症检测的强度和宣传宣传活动
    • 医疗基础设施和医疗支出的增加
  • 市场限制因素
    • 与研发相关的高成本
  • 市场机会
    • 用于检测侵袭性肝癌的优质生物标记的出现
    • 积极的研究活动旨在引入新的生物标记以早期检测肺癌
  • 市场挑战
    • 复杂而严格的规定

波特的五力：驾驭癌症生物标记市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解癌症生物标记市场的外部影响

外部宏观环境因素在塑造癌症生物标记市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症生物标记市场的竞争格局

癌症生物标记市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癌症生物标记市场供应商的绩效评估

FPNV定位矩阵是评估癌症生物标记市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製癌症生物标记市场的成功之路

癌症生物标记市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人群中癌症盛行率增加
      • 增加早期癌症检测的强度和宣传宣传活动
      • 扩大医疗基础设施和医疗支出
    • 抑制因素
      • 研发成本高
    • 机会
      • 用于检测恶性肝癌的更好生物标记的出现
      • 积极的研究活动旨在引入新的生物标记以早期检测肺癌
    • 任务
      • 复杂且严格的监管合规
  • 市场区隔分析
    • 生物标记的类型：蛋白质生物标记效用透过血液和组织中所含的蛋白质检测癌症的存在
    • 应用：诊断中优先选择生物标记以进行早期检测，以改善患者的治疗结果
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按生物标记类型分類的癌症生物标记市场

  • 遗传的
  • 蛋白质

第 7 章按癌症类型分類的癌症生物标记市场

  • 血癌
  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 卵巢癌
  • 摄护腺癌
  • 皮肤癌
  • 胃癌

第八章癌症生物标记市场：依技术分类

  • 生物资讯学
  • 细胞遗传学
  • 成像技术
  • 免疫检测
  • 体学技术

第九章癌症生物标记市场：依应用分类

  • 诊断
  • 药物发现与开发
  • 预言
  • 风险评估

第 10 章癌症生物标记市场：按最终用户分类

  • 学术/癌症研究中心
  • 医院
  • 专业中心

第十一章美洲癌症生物标记市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区癌症生物标记市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的癌症生物标记市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Chromacord 与乔治亚医学院结成策略联盟，加强 NSCLC 诊断能力
    • 晶泰科技与CK Life Sciences加强人工智慧合作，打造下一代癌症诊断
    • 提高癌症治疗的准确性：FDA启动试验计画来规范肿瘤药物的伴同性诊断测试
  • 战略分析和建议

公司名单

  • Abbott Laboratories Inc.
  • Agilent Technologies, Inc.
  • ASURAGEN, INC.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Bruker Corporation
  • Charles River Laboratories International, Inc.
  • Enzo Biochem, Inc.
  • Epigenomics AG
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthcare GmbH
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-437517DB6E4D

The Cancer Biomarkers Market was valued at USD 28.31 billion in 2023, expected to reach USD 31.23 billion in 2024, and is projected to grow at a CAGR of 10.71%, to USD 57.75 billion by 2030.

Cancer biomarkers are biological molecules found in blood, other body fluids, or tissues, indicating the presence of cancer. Their scope includes detection, diagnosis, prognosis, and therapeutic monitoring, making them critical in personalized medicine. Cancer biomarker research is essential for early detection, more accurate diagnoses, and tailored treatments that improve patient outcomes. They are extensively applied in clinical diagnostics, drug discovery, and development as well as cancer research, radiology, and pathology. The end-use scope spans hospitals, research laboratories, diagnostic centers, and biotechnology and pharmaceutical companies. Key growth factors include the rising prevalence of cancer, increased funding for cancer genomics research, technological advancements in omics technologies, and growing demand for non-invasive testing procedures. Potential opportunities lie in advancements in proteomics, genomics, and bioinformatics, which may uncover novel biomarkers, and in emerging markets where healthcare infrastructure is rapidly improving. However, the market faces challenges such as high costs of biomarker discovery and validation, regulatory complexities, and variability in biomarker expression that can impact the interpretation of results. To overcome these, leveraging big data analytics and artificial intelligence to enhance predictive accuracy and integrating multi-omics data to discover more precise markers are crucial. Best areas for innovation include developing liquid biopsy technologies, exploring microRNA and exosome-based biomarkers, and improving point-of-care testing capabilities. Collaborations between academic institutions, healthcare providers, and biotech firms can accelerate innovation and bring new solutions to market. The cancer biomarker market is highly dynamic and competitive, characterized by rapid technological evolution and a constant drive for innovation to meet the pressing demands of early cancer detection and personalized treatment. Adoption of next-generation sequencing (NGS) technologies and the exploration of integrative approaches like artificial intelligence in data analysis could offer a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 28.31 billion
Estimated Year [2024] USD 31.23 billion
Forecast Year [2030] USD 57.75 billion
CAGR (%) 10.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biomarkers Market

The Cancer Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer disorders among population
    • Rising initiatives and awareness campaigns for early cancer detection
    • Growing healthcare infrastructure and healthcare spending
  • Market Restraints
    • High costs associated with research and development
  • Market Opportunities
    • Emergence of better biomarkers for detection of aggressive liver cancer
    • Robust research activities to introduce new biomarkers for early detection of lung cancer
  • Market Challenges
    • Complex and stringent regulatory compliances

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biomarkers Market

A detailed market share analysis in the Cancer Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biomarkers Market

A strategic analysis of the Cancer Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Agilent Technologies, Inc., ASURAGEN, INC., Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Charles River Laboratories International, Inc., Enzo Biochem, Inc., Epigenomics AG, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hologic, Inc., Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., PerkinElmer, Inc., Pfizer Inc., QIAGEN N.V, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Biomarker Type, market is studied across Genetic and Protein.
  • Based on Cancer Type, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Skin Cancer, and Stomach Cancer.
  • Based on Technology, market is studied across Bioinformatics, Cytogenetics, Imaging Technology, Immunoassays, and OMICS Technology.
  • Based on Application, market is studied across Diagnostics, Drug Discovery & Development, Prognostics, and Risk Assessment.
  • Based on End User, market is studied across Academic & Cancer Research Centers, Hospitals, and Speciality Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disorders among population
      • 5.1.1.2. Rising initiatives and awareness campaigns for early cancer detection
      • 5.1.1.3. Growing healthcare infrastructure and healthcare spending
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of better biomarkers for detection of aggressive liver cancer
      • 5.1.3.2. Robust research activities to introduce new biomarkers for early detection of lung cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Complex and stringent regulatory compliances
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarker Type: Usability of protein biomarkers in detecting the presence of cancer through proteins found in blood or tissue
    • 5.2.2. Application: Preferences for biomarkers in diagnostic for early-stage detection to improve treatment outcomes for patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Biomarkers Market, by Biomarker Type

  • 6.1. Introduction
  • 6.2. Genetic
  • 6.3. Protein

7. Cancer Biomarkers Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Blood Cancer
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Ovarian Cancer
  • 7.7. Prostate Cancer
  • 7.8. Skin Cancer
  • 7.9. Stomach Cancer

8. Cancer Biomarkers Market, by Technology

  • 8.1. Introduction
  • 8.2. Bioinformatics
  • 8.3. Cytogenetics
  • 8.4. Imaging Technology
  • 8.5. Immunoassays
  • 8.6. OMICS Technology

9. Cancer Biomarkers Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostics
  • 9.3. Drug Discovery & Development
  • 9.4. Prognostics
  • 9.5. Risk Assessment

10. Cancer Biomarkers Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Cancer Research Centers
  • 10.3. Hospitals
  • 10.4. Speciality Centers

11. Americas Cancer Biomarkers Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cancer Biomarkers Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cancer Biomarkers Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities
    • 14.3.2. Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics
    • 14.3.3. Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories Inc.
  • 2. Agilent Technologies, Inc.
  • 3. ASURAGEN, INC.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Bristol-Myers Squibb Company
  • 7. Bruker Corporation
  • 8. Charles River Laboratories International, Inc.
  • 9. Enzo Biochem, Inc.
  • 10. Epigenomics AG
  • 11. Eurofins Scientific SE
  • 12. Exact Sciences Corporation
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. GE HealthCare Technologies Inc.
  • 15. Hologic, Inc.
  • 16. Illumina, Inc.
  • 17. Merck KGaA
  • 18. Myriad Genetics, Inc.
  • 19. PerkinElmer, Inc.
  • 20. Pfizer Inc.
  • 21. QIAGEN N.V
  • 22. Quest Diagnostics Incorporated
  • 23. Siemens Healthcare GmbH
  • 24. Sysmex Corporation
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC & CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 244. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023